Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world

Madan Raj Aryal, Rohit Gosain, Anthony Donato, Han Yu, Anjan Katel, Yashoda Bhandari, Rashmi Dhital and Peter A. Kouides

Data supplements

Article Figures & Data



  • Table 1.

    Baseline characteristics of included studies

    Sindet-Pedersen et al,8 2018Lutsey et al,14 2019Bott-Kitslaar,9 2018Dawwas et al,10 2019Howe et al,11 2018
    Source typeJournal articleJournal articleJournal articleJournal articleJournal article
    Study designRetrospective, multicenter registryRetrospective, market scan data warehouseProspective, single-center trial (Mayo Thrombophilia Clinic Registry), observationalRetrospective cohort analysis, market scan and Medicare supplement claims 2014-2016Retrospective review, single VA center
    Mean age, y70 A*60.4 A62.4 A61.5 A73 A
    67 R*56.4 R58.5 R56.5 R68 R
    Female sex, %50.8 A50.3 A38.7 A50.6 A2 A
    45.3 R49.2 R48 R49.5 R4.4 R
    Mean weight, kgNSNS87.6 ANSNS
    91.3 R
    Medications, %23.6 A7 A23.8 A7.3 ANS
     Antiplatelet agents18.3 R5.1 R21.8 R4.2 R
    Comorbidities, %14 A17 A47 A17.7 ANS
     Malignancy11.4 R16.1 R39.9 R18.9 R
    Chronic kidney3.9 A13.2 A2.3 A17.1 ANS
    2.7 R7.1 R0 R8.5 R
    Total duration of study, mo29 58 2424
    Study groups (total no. of patients in each group)2 groups2 groups2 groups2 groups2 groups
    A (1504)A (6786)A (302)A (3091)A (89)
    R (6683)R (30 982)R (298)R (12 163)R (173)
    Primary outcomeAll-cause mortality, recurrent VTE, hospitalized bleedingHospitalized bleedingVTE recurrence, major bleeding eventsVTE recurrence, major bleeding eventsOverall bleeding rates
    Secondary outcomeIntracranial and gastrointestinal bleedingCRNMB, and composite of major bleeding and CRNMBMinor bleeding eventsTime to bleeding and location of bleeding
    Recurrent VTE, %1.71 ANS2.32 A0.81 ANS
    1.76 R2.01 R2.09 R
    Major bleeding, %1.17 A0.74 A3.64 A0.91 A0.56 A
    1.28 R1.15 R3.20 R1.55 R1.99 R
    Nonmajor/minor bleeding, %NSNS2.32 A5.37 A0.28
    6.71 R8.90 R1.77 R
    Study outcomes reported atAverage 6 mo3 mo and 6 mo3 mo and overall as 100 per year incidence<3 mo and >3 mo and 100 person-yearAt 3 mo and 100 person-year
    Major outcomes reported asIncidence reported as percent events, ARR between 2 groupsAdjusted HR for 100 person-year incidence, number of events at 3 moNo. of events at <3 mo and >3 mo, HR for the same and also for 100 person-year incidenceNo. of events at 3 mo and 100 person-year incidence
    • A, apixaban; ARR, absolute risk reduction; CRNMB, clinically relevant nonmajor bleeding; NS, not specified; R, rivaroxaban; VA, Veterans Affairs; W, warfarin.

    • * Median.

    • Creatinine clearance <30 mL/min.